Skip to main content

Microdose Buprenorphine Initiation for Opioid Use Disorder

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Microdose Buprenorphine Initiation for Opioid Use Disorder

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Submitted by Anonymous (not verified) on Fri, 07/28/2023 - 14:45
  • Read more about Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • …
  • Next page Next
  • Last page Last
Subscribe to